Masked by the Mass: Paraneoplastic Minimal Change Disease Revealing Classic Hodgkin Lymphoma

Introduction: Paraneoplastic minimal change disease (MCD) is a cytokine-driven podocytopathy that rarely complicates classical Hodgkin lymphoma (cHL), and durable renal remission hinges on curing the malignancy rather than prolonged glucocorticoids. Documented in <1% of cHL cases, MCD may precede the lymphoma diagnosis. Case Description: A 25-year-old man presented with three weeks of 3+ leg edema, night sweats, 4.5 kg weight loss, and pleuritic chest pain. CT angiography demonstrated a 9.5 cm anterior mediastinal mass with pleural effusion. Labs: creatinine 4.39 mg/dL, albumin 1.8 g/dL, cholesterol 348 mg/dL, UPCR >6.5 g/g, bland sediment, urine Na <10 mmol. Initial considerations included NSAID-induced acute interstitial nephritis, and high-dose prednisone was empirically started. Kidney biopsy on day 6 revealed normal glomeruli, negative immunofluorescence, and >90% podocyte foot-process effacement confirming MCD. Prednisone was tapered rapidly. Excisional supraclavicular node biopsy proved Stage IIB nodular-sclerosis cHL (CD30/CD15) Nivolumab plus AVD chemotherapy began on day 7. By week 2, creatinine decreased to 1.36 mg/dL, albumin rose to 2.5 g/dL, and UPCR fell to 0.4 g/g. A month review showed complete resolution of edema and ongoing renal remission while he continued nivolumab-AVD Discussion: MCD should be considered in the differential when young adults with lymphoma develop AKI and heavy proteinuria, especially in the absence of hematuria or serologic autoimmunity. The pathogenesis involves cytokine-mediated podocyte injury, including potential IL-13 pathways, leading to the destabilization of slit diaphragms and nephrotic-range proteinuria. This case reinforces several clinical pearls: 1) Biopsy early. KDIGO 2021 recommends biopsy when nephrotic syndrome coexists with AKI or systemic signs. 2) Treat the tumor. >80% remit once lymphoma therapy is initiated; relapse tracks tumor burden. 3) Use Immunosuppression Judiciously. Biopsy should guide decisions; reflex steroid use may be counterproductive.Creatinine trend over time

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-10-01
DOI
https://doi.org/10.1681/asn.20259skmjng7
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Masked by the Mass: Paraneoplastic Minimal Change Disease Revealing Classic Hodgkin Lymphoma

Hassan Y.A.H. Mahmoud, Cani Greg Garsuta
Journal of the American Society of Nephrology
Autoimmune Neurological Disorders and Treatments
article

Masked by the Mass: Paraneoplastic Minimal Change Disease Revealing Classic Hodgkin Lymphoma

Hassan Y.A.H. Mahmoud, Cani Greg Garsuta
article en

Abstract

Introduction: Paraneoplastic minimal change disease (MCD) is a cytokine-driven podocytopathy that rarely complicates classical Hodgkin lymphoma (cHL), and durable renal remission hinges on curing the malignancy rather than prolonged glucocorticoids. Documented in <1% of cHL cases, MCD may precede the lymphoma diagnosis. Case Description: A 25-year-old man presented with three weeks of 3+ leg edema, night sweats, 4.5 kg weight loss, and pleuritic chest pain. CT angiography demonstrated a 9.5 cm anterior mediastinal mass with pleural effusion. Labs: creatinine 4.39 mg/dL, albumin 1.8 g/dL, cholesterol 348 mg/dL, UPCR >6.5 g/g, bland sediment, urine Na <10 mmol. Initial considerations included NSAID-induced acute interstitial nephritis, and high-dose prednisone was empirically started. Kidney biopsy on day 6 revealed normal glomeruli, negative immunofluorescence, and >90% podocyte foot-process effacement confirming MCD. Prednisone was tapered rapidly. Excisional supraclavicular node biopsy proved Stage IIB nodular-sclerosis cHL (CD30/CD15) Nivolumab plus AVD chemotherapy began on day 7. By week 2, creatinine decreased to 1.36 mg/dL, albumin rose to 2.5 g/dL, and UPCR fell to 0.4 g/g. A month review showed complete resolution of edema and ongoing renal remission while he continued nivolumab-AVD Discussion: MCD should be considered in the differential when young adults with lymphoma develop AKI and heavy proteinuria, especially in the absence of hematuria or serologic autoimmunity. The pathogenesis involves cytokine-mediated podocyte injury, including potential IL-13 pathways, leading to the destabilization of slit diaphragms and nephrotic-range proteinuria. This case reinforces several clinical pearls: 1) Biopsy early. KDIGO 2021 recommends biopsy when nephrotic syndrome coexists with AKI or systemic signs. 2) Treat the tumor. >80% remit once lymphoma therapy is initiated; relapse tracks tumor burden. 3) Use Immunosuppression Judiciously. Biopsy should guide decisions; reflex steroid use may be counterproductive.Creatinine trend over time

Journal of the American Society of NephrologyVol. 36(10S)
MaineHealth (US)
Openalex Percentile: Top 57%
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Masked by the Mass: Paraneoplastic Minimal Change Disease Revealing Classic Hodgkin Lymphoma — Hassan Y.A.H. Mahmoud, Cani Greg Garsuta · Journal of the American Society of Nephrology (2025) | TGRS Research Map | TGRS